CD4+ Cell Count, Lipid And Lipoprotein Levels In Hiv Patients On Drug Treatment

Adedokun Kamoru A, Olisekodiaka Japhet M, Adeyeye Adetunji D, Adepeju Akinlawon A, Muhibi Musa A, Onifade Abdufatah A, Laoye Jelili A, Adetoro Taofik A, UGWU Prince I, Oyenike Musiliu A
2017 Figshare  
Previous reports showed lack of consensus on the possible etiology of coronary artery disease (CAD) between HIV-treatment with highly active antiretroviral therapy (HAART) and HIV-infection in particular. The aim of this study was to find out correlations of HIV-treatment and HIV-infection with CAD risk. Method: One hundred and twenty (120) participants involving HIV-patients on treatment (n = 40), treatment-naïve (n = 40) and equal number of age- and sex-matched controls were enrolled. The
more » ... e enrolled. The total cholesterol, triglycerides and lipoprotein (HDL-C) were analyzed using spectrophotometry. The LDL-C was calculated using Friedewald equation, TC/HDL-C and LDL-C/HDL-C ratios were also calculated. The CD4+ cell count was determined using flow cytometry. Result: The mean plasma total cholesterol levels in patients' groups on treatment and treatment-naïve were significantly reduced when compared with controls, but the mean triglyceride levels for both treatment and the treatment-naïve groups were significantly increased when compared with controls. However, HDL-C and LDL-C values for patients on HAART and the treatment-naive were significantly reduced when compared with controls respectively. The CAD risk predictors, LDL-c and TC/HDL-C ratio, were significantly increased in patients on HAART when compared with the treatment-naive. The mean CD4+ cell count in treatment-naive was significantly lowered against both groups for treatment and controls. Conclusion: In this present study, abnormal lipid profile was associated with both HIV-infection and HAART-treatment. However, TC/HDL-C ratio, the strong predictor of CAD events in metabolic disorder was markedly high in HAARTtreatment and the associated difference may threaten higher risk for cardiovascular disease (CVD) during treatment.
doi:10.6084/m9.figshare.5674765.v1 fatcat:dzojkam2wrav7ett2oh77ktnxu